Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET-rearranged thyroid cancer.

Raman, Renuka; Villefranc, Jacques A; Ullmann, Timothy M; Thiesmeyer, Jessica; Anelli, Viviana; Yao, Jun; Hurley, James R; Pauli, Chantal; Bareja, Rohan; Wha Eng, Kenneth; Dorsaint, Princesca; Wilkes, David C; Beg, Shaham; Kudman, Sarah; Shaw, Reid; Churchill, Michael; Ahmed, Adnan; Keefer, Laurel; Misner, Ian; Nichol, Donna; ... (2022). Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET-rearranged thyroid cancer. Journal of experimental medicine, 219(6) Rockefeller University Press 10.1084/jem.20210390

[img]
Preview
Text
jem_20210390.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (5MB) | Preview

Genetic alterations in RET lead to activation of ERK and AKT signaling and are associated with hereditary and sporadic thyroid cancer and lung cancer. Highly selective RET inhibitors have recently entered clinical use after demonstrating efficacy in treating patients with diverse tumor types harboring RET gene rearrangements or activating mutations. In order to understand resistance mechanisms arising after treatment with RET inhibitors, we performed a comprehensive molecular and genomic analysis of a patient with RET-rearranged thyroid cancer. Using a combination of drug screening and proteomic and biochemical profiling, we identified an adaptive resistance to RET inhibitors that reactivates ERK signaling within hours of drug exposure. We found that activation of FGFR signaling is a mechanism of adaptive resistance to RET inhibitors that activates ERK signaling. Combined inhibition of FGFR and RET prevented the development of adaptive resistance to RET inhibitors, reduced cell viability, and decreased tumor growth in cellular and animal models of CCDC6-RET-rearranged thyroid cancer.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Präzisionsonkologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Präzisionsonkologie

UniBE Contributor:

Rubin, Mark Andrew

ISSN:

1540-9538

Publisher:

Rockefeller University Press

Language:

English

Submitter:

Pubmed Import

Date Deposited:

06 May 2022 09:14

Last Modified:

05 Dec 2022 16:19

Publisher DOI:

10.1084/jem.20210390

PubMed ID:

35510953

BORIS DOI:

10.48350/169770

URI:

https://boris.unibe.ch/id/eprint/169770

Actions (login required)

Edit item Edit item
Provide Feedback